Despite this caveat, hematopoietic stem/progenitor cell (HSPC) antigens with increased expression on AML blasts, such as CD33, CD123, and CLL1 (CLEC12A), have emerged as potential targets. The gene discussed is CLEC12A; the disease is acute myeloid leukemia.